Britten C - Search Results

1

t(2;5) positive lymphoma with peripheral blood involvement.

Chhanabhai M, Britten C, Klasa R, Gascoyne RD. Chhanabhai M, et al. Among authors: britten c. Leuk Lymphoma. 1998 Jan;28(3-4):415-22. doi: 10.3109/10428199809092698. Leuk Lymphoma. 1998. PMID: 9517514

2

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.

Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. Gelmon KA, et al. Among authors: britten c. Invest New Drugs. 2005 Oct;23(5):445-53. doi: 10.1007/s10637-005-2904-2. Invest New Drugs. 2005. PMID: 16133796 Clinical Trial.

3

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.

Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Davis AJ, et al. Invest New Drugs. 2003 Feb;21(1):85-97. doi: 10.1023/a:1022976528441. Invest New Drugs. 2003. PMID: 12795533 Clinical Trial.

4

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.

Kollmannsberger C, Britten CD, Olszanski AJ, Walker JA, Zang W, Willard MD, Radtke DB, Farrington DL, Bell-McGuinn KM, Patnaik A. Kollmannsberger C, et al. Among authors: britten cd. Invest New Drugs. 2021 Dec;39(6):1613-1623. doi: 10.1007/s10637-021-01146-x. Epub 2021 Jul 15. Invest New Drugs. 2021. PMID: 34264412 Clinical Trial.

5

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A. Guo F, et al. Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. doi: 10.1007/s00280-007-0579-4. Epub 2007 Sep 6. Cancer Chemother Pharmacol. 2008. PMID: 17805538 Clinical Trial.

6

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. Munster PN, et al. Clin Cancer Res. 2007 Feb 15;13(4):1238-45. doi: 10.1158/1078-0432.CCR-06-1539. Clin Cancer Res. 2007. PMID: 17317835 Clinical Trial.

7

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM. Britten CD, et al. Invest New Drugs. 2014 Jun;32(3):510-7. doi: 10.1007/s10637-013-0062-5. Epub 2014 Jan 7. Invest New Drugs. 2014. PMID: 24395457 Clinical Trial.

8

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Diamond JR, et al. Among authors: britten cd. Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10. Invest New Drugs. 2017. PMID: 28283779 Free PMC article. Clinical Trial.

9

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.

von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. von Mehren M, et al. Invest New Drugs. 2014 Jun;32(3):518-25. doi: 10.1007/s10637-014-0064-y. Epub 2014 Jan 24. Invest New Drugs. 2014. PMID: 24458261 Free PMC article. Clinical Trial.

10

A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.

Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD, Eckhardt SG. Britten CD, et al. Clin Cancer Res. 2000 Jan;6(1):42-9. Clin Cancer Res. 2000. PMID: 10656430 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters